NDASUBCUTANEOUSSOLUTION
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
BREKIYA (AUTOINJECTOR) (dihydroergotamine mesylate) by Baxter is 5-ht 1dα and 5-ht 1dβ receptors. Approved for migraine. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREKIYA is a subcutaneous autoinjector formulation of dihydroergotamine mesylate approved in May 2025 for acute migraine treatment. It works by agonizing 5-HT1D receptors to rapidly abort migraine attacks. The autoinjector delivery format offers patients a convenient, self-administered alternative to traditional ergot therapeutics.
Launch12.8 years to LOE
Recently launched product with significant patent protection through 2039 offers growth trajectory potential, though team size remains to be determined in market.
Mechanism of Action
5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.
Indications (1)
Clinical Trials (1)
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Started Mar 2010
24 enrolled
Healthy
Career Relevance
BREKIYA represents a fresh launch opportunity with meaningful patent protection, attracting talent to establish brand infrastructure and capture market share in the highly competitive migraine space. Career growth potential is strongest in commercial roles targeting rapid market penetration and differentiation versus entrenched CGRP competitors.
Worked on BREKIYA (AUTOINJECTOR) at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.